Device Trial Radar · NCT03366155
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jun 24, 2019
Primary completion
Nov 13, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A device that does this a pump that delivers drugs over 2 weeks at constant rate into the hepatic artery. The person's body temperature causes the drug to flow from the pump. Researchers want to see if this helps people with colorectal metastases to the liver. Objective: To study the effectiveness of a hepatic artery infusion pump at treating colorectal metastases to the liver. Eligibility: Adults at least 18 years old with colorectal metastases to the liver Design: Participants will be screened with: Medical history Physical exam Heart, blood, and urine tests Scans Participants will stay in the hospital a few days. A small plastic tube (catheter) will be inserted in an artery into the liver. The catheter will be attached to the pump. That will lie under the skin on the abdomen. It will be small and participants will be able to feel it. Participants will get treatment in 28-day cycles. Every Day 1, they will have physical exam, symptom review, and blood tests. Every 2 weeks, they will come to the clinic to get chemotherapy by a catheter or port. Every 12 weeks, they will have a scan. Tissue samples may be taken during the study. When they finish the drug, participants may have the pump removed. They will repeat the Day 1 tests. They will be called every 6 months to see how they are doing.
Conditions
- Colorectal Cancer
- Liver Metastases
- Colorectal Adenocarcinoma
- Colorectal Cancer With Hepatic Metastases
- Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheterDevice
Implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
PanitumumabDrug
6 mg/kg, intravenous (IV)
FUDR-DexDrug
Hepatic Artery Infusion Pump (HAIP) will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate), Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
OxaliplatinDrug
85 mg/m\^2, intravenous (IV)
5FUDrug
2000 mg/m\^2, intravenous (IV) 46-hour infusion of 5-Fluorouracil + 400 mg/m\^2, IV of Leucovorin
IrinotecanDrug
150 mg/m\^2, intravenous (IV)
HAIP installationProcedure
Hepatic Artery Infusion (HAI) pump installation
cetuximabDrug
500 mg/m\^2, intravenous (IV)
Medtronic SynchroMed II PumpDevice
Implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
FloxuridineDrug
Floxuridine 0.12 mg/kg X pump volume X pump flow rate
DexamethasoneDrug
1 mg/day X pump volume (30) X pump flow rate
EKGDiagnostic test
Screening and baseline.
CT C/A/PDiagnostic test
Screening, baseline and Cycle 1. One cycle is 28 (+/- 2 days).
CT Angiogram (abdomen)Diagnostic test
Screening
Tumor and normal liver biopsyProcedure
For research: During surgery to install pump, time of progression per principal investigator discretion if safe, and end of treatment.
LeucovorinDrug
400 mg/m\^2, intravenous (IV), (Day15, Day1)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response Rate (RR) Reported With an 80% Confidence IntervalTime frame: 6 months
- Response Rate (RR) Reported With a 95% Confidence IntervalTime frame: 6 months
- Number of Grade 1, 2, 3, 4, and/or 5 Serious and/or Non-serious Adverse Events Reported With Type and FrequencyTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institutes of Health Clinical Center
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.